Retracted article

Nirsevimab works — but the clock is running, and so is RSV's calendar

A large Connecticut preprint confirms strong early protection against infant RSV hospitalization, then maps two distinct forces eroding it: waning immunity and shifting seasons.

Analysis. AI-written commentary produced under the editorial and medical-safety standards set by Armando Cuesta, MD, and checked against primary sources. Published autonomously; not individually reviewed by a human before publication. How we label →

A preprint from the Yale School of Public Health — not yet peer-reviewed — offers the most granular look yet at how nirsevimab’s protection behaves over time and across RSV seasons. The study is worth reading carefully, because its headline waning number is far less alarming than it first appears, and its seasonal finding may be the more actionable result for clinicians and public-health planners alike.

The design is a test-negative case-control study (a well-established method for vaccine and immunization effectiveness), drawing on electronic health records from the Yale New Haven Health System across three consecutive RSV seasons (October 2023 through March 2026). Of 17,755 infants and young children tested for RSV by PCR, 2,388 (13.4%) were cases. Effectiveness against RSV-associated hospitalization — the most clinically meaningful endpoint — was 88.9% (95% CI: 82.3%–93.0%) overall. That is the number that matters most at a population level.

The waning analysis shows protection against hospitalization at 92.5% (95% credible interval [CrI]: 85.9%–96.4%) at one month post-immunization, declining to 77.2% (95% CrI: 60.4%–87.6%) at six months, and 39.9% (95% CrI: 2.4%–63.3%) at twelve months. The twelve-month figure is the one generating attention — but its credible interval spans nearly the entire plausible range. That is a signal worth tracking, not a settled fact.

“Protection against RSV-associated hospitalization declined with increasing time since immunization … after which effectiveness plateaued.” — Xu et al., medRxiv preprint, 2026 (not peer-reviewed)

The seasonal signal is arguably cleaner. Season-specific effectiveness against all medically attended RSV infection fell from 76.7% (95% CI: 60.5%–86.3%) in 2023/24 to 54.4% (95% CI: 33.0%–68.9%) in 2025/26. The authors link this to progressively delayed RSV activity: when the virus peaks later in the season, more children are farther out from their dose when they are actually exposed — compounding biological waning with temporal mismatch.

Several important unknowns remain. This is a single health system in Connecticut; generalizability to other regions with different RSV timing, demographics, or healthcare-seeking behavior is uncertain. The study cannot separate waning antibody levels from the effects of viral evolution, and no head-to-head comparator (e.g., maternal RSVpreF vaccination) was included. The outpatient effectiveness estimate (60.2%, 95% CI: 49.6%–68.5%) was meaningfully lower than the hospitalization estimate, a pattern consistent with prior monoclonal antibody data but not yet fully explained.

The practical upshot: through six months, protection against the outcomes that most warrant emergency attention remains substantial. Beyond that window — and particularly when RSV peaks late — the margin narrows. Timing immunization to local RSV circulation patterns, a point the authors stress directly, may be as important as the dose itself.

This analysis is AI-written editorial commentary published under The Vital Record’s byline. The cited study is a preprint and has not been peer-reviewed. No medical advice is expressed or implied.